Congress forces breakup of pharmacy-insurance giants to restore drug competition

What it does

This bill prohibits pharmacy benefit managers (PBMs) and pharmacies from being owned by the same company, and requires companies that currently own both to divest their pharmacy businesses within one year. It empowers the FTC, DOJ, state attorneys general, and private citizens to sue for violations, with penalties including treble damages, profit escrow, and forced divestiture. The bill aims to reduce conflicts of interest in drug pricing and restore competition to independent pharmacies.

Why we flagged it

The bill's core mechanism is forced structural separation of vertically integrated health conglomerates—a direct antitrust remedy targeting conflicts of interest in pharmaceutical supply chains, not a regulatory tweak or price control.

What the text implies

• Divestiture may trigger significant market disruption: UnitedHealth, CVS Health, Cigna, and Aetna (the largest integrated PBM-pharmacy-insurer conglomerates) would be forced to separate, potentially creating three separate publicly traded entities from each, with uncertain financial viability and integration costs borne by shareholders and possibly passed to consumers.
• The private right of action with treble damages and attorney's fees creates litigation risk for any entity that delays or disputes divestiture, potentially generating years of class-action litigation and settlement pressure independent of regulatory enforcement.
• Profit escrow (10% monthly) during non-compliance creates a powerful financial incentive to divest quickly, but also creates a pool of contested funds that may be tied up in litigation if companies challenge the divestiture deadline or methodology.
• The bill grants state attorneys general parens patriae authority to sue on behalf of residents, creating 50 parallel enforcement tracks and potential for conflicting state-level interpretations or settlements that fragment the national market.
• FTC and DOJ review of divestitures under Clayton Act Section 7A may slow or block divestitures if regulators determine the acquiring entity would recreate conflicts of interest, potentially leaving companies in limbo and unable to complete the required separation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens benefit from restored competition in pharmacy markets, lower prescription drug costs, and protection of independent pharmacies. The bill directly addresses documented conflicts of interest where integrated PBMs steer business to their own pharmacies, raising prices and closing competitors. Patients and taxpayers gain from reduced profit-hiding through transfer pricing.

Who stands to gain

• independent pharmacies (restored competitive access and pricing power)
• patients and health plan enrollees (lower drug prices, broader pharmacy choice)
• state and federal governments (reduced Medicaid/Medicare overpayments, recovered disgorged profits)

Named in the bill

Pharmacy Benefit Managers (PBMs), UnitedHealth Group, CVS Health, Cigna, Aetna, Humana, Walgreens, Rite Aid, independent pharmacies, Federal Trade Commission (FTC), Department of Justice (DOJ), state attorneys general — and 4 more

Where it stands

8 cosponsors: 5 Democrats, 3 Republicans.

• May 13, 2026 — Introduced · Congress.gov: “Introduced in House”
• May 13, 2026 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,842,990 in lobbying spend. A filing names 37 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Diana Harshbarger, the sponsor, reported $747,520 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• National Association of Chain Drug Stores — $290,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.